In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support: require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.”
In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support: require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.” Nearly 70% of respondents back this strategy, according to a survey sponsored by the Kaiser Family Foundation (KFF), the Robert Wood Johnson Foundation and the Harvard School of Public Health. That’s far more than the mere 32% who want to raise Medicare premiums or the 26% who support a higher Medicare eligibility age (67, up from 65 years).
Most notable is the surprisingly strong bipartisan support for this hit on pharma: 61% of Republicans “strongly favor” this action, as do 77% of Democrats, according to this January poll. Congressional Democrats have been pressing hard to require pharma companies to pay rebates on drugs provided to Medicare “dual eligible” beneficiaries who qualify for assistance from state Medicaid programs and previously received prescription drugs through state plans that collect rebates.
Meanwhile, most of the 1347 people surveyed want to keep funds flowing to other government health-related programs, such as veteran’s health, anti-terrorist preparations, research to find new cures and treatments, and actions to prevent chronic illnesses and the spread of infectious diseases. Less than half (47%) back government funding of “programs to ensure the safety and effectiveness of prescription drugs,” reflecting less enthusiasm for FDA operations.
The biggest surprise for the pollsters was the relatively strong backing – from both Democrats and Republicans – for state governments to establish health insurance exchanges this year. More than half (55%) of those answering the survey list creating exchanges, or “marketplaces,” as a top priority.
Although most respondents– particularly Republicans – want quick action to tackle the federal budget deficit, there’s not much consensus on where the axe should fall. No surprise that Democrats prefer to raise taxes, while Republicans want to reduce federal spending. The most popular revenue-raiser is to hike taxes for people making more than $400,000 a year. But the majority opposes reductions in spending on education, Medicare, and social security – and economists say that any serious budget cutting has to hit those programs.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.